Zentek Ltd. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand Zentek Ltd.’s latest annual report. My goal is to cut through the corporate jargon and explain what is actually happening at the company so you can decide if it fits your portfolio.

1. What does this company do?

Zentek is a Canadian tech company that develops and sells graphene-based products. Think of them as an "intellectual property" shop. They research advanced materials and license their technology to industries like healthcare and manufacturing.

Their main focus is ZenGUARD™, a graphene coating for protective gear and air filters. They are also exploring energy storage and ice-repelling coatings. As of March 31, 2026, they trade on the TSX Venture Exchange (ZEN) and the Nasdaq (ZTEK). Because they are an early-stage company, they are focused on proving their technology works and finding commercial partners.

2. Financial health and debt

Zentek is an "emerging growth company." This means they spend more on research than they earn from sales. For the year ending March 31, 2026, the company reported a loss, which is typical for a business in its early stages. They do not pay dividends or buy back shares.

As of March 31, 2026, they had 107,792,002 shares outstanding. Watch this number closely. If it grows, the company is issuing more shares, which reduces your ownership percentage.

The company has a clean balance sheet with no hidden debt. Their total contractual obligations are $1.48 million (USD):

• $227,000 is due within one year (mostly for office leases).
• $1.256 million is due in 1–3 years (long-term debt).
• They have no major debt payments due after three years.

3. Governance and oversight

Zentek follows Canadian reporting rules. Eric Wallman leads their Audit Committee, bringing financial expertise to the oversight of their books. They use BDO Canada LLP as their independent auditor.

4. Major risks

Investing in Zentek comes with significant early-stage risks:

• Sales Cycles: They face long, unpredictable sales cycles. Having a product does not guarantee a buyer.
• Regulations: They work in strict sectors like healthcare. Government approval delays or new regulations can stall their business.
• Market Volatility: As a small tech company, their stock price can swing wildly based on news.
• Capital Needs: They currently lose money. They will likely need to raise more cash in the future, which could mean issuing more shares and reducing your ownership percentage.
• Operations: They rely on key staff and suppliers. If they lose a top scientist or a supplier fails, the business suffers.
• Patents: Their business depends on protecting their graphene technology. If they fail to defend their patents, competitors could copy their products.

5. Competitive positioning

Zentek’s success depends on their patents and how fast they reach the market. There is no established market for graphene yet, so they are essentially building one from scratch. Their edge depends on scaling production and securing long-term supply deals.

6. Future outlook

The company must turn research into consistent profit. Your investment is a bet on their future technology, not their current cash flow. They are in a "prove it" phase, moving from the lab to large-scale sales.

Final Thought for Investors: When looking at a company like Zentek, ask yourself if you are comfortable with a "high-risk, high-reward" profile. Since they are still in the development phase, your primary focus should be on their ability to secure commercial contracts and manage their cash reserves without diluting shareholders too heavily.

Disclaimer: I am an AI, not a financial advisor. This guide is for educational purposes and is not investment advice. Always do your own research before buying stocks.